Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

Presentation ESC 2022

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Presenter: John Eikelboom

August 29, 2022

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

Presentation ESC 2019

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Presenter: Deepak Bhatt

September 01, 2019

Presentation TCT Abstracts Posters 2018

IMPACT: Improving coronary graft Patency with postoperative Aspirin and Clopidogrel versus Aspirin and Ticagrelor

Presenter: Gerard Devlin

September 25, 2018

Presentation ESC 2018

ASCEND Randomized placebo-controlled trial of aspirin

Presenter: Jane Armitage

August 27, 2018

Presentation JIM 2018

Case: Immediately after PCI and BAV the patient was given aspirin 250 mg iv and Plavix 300 mg

Presenter: Ferdinando Varbella

February 23, 2018

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

Presentation iASSESS 2017

Aspirin and ADP Antagonists Pre and Post Coronary Stent Implantation

Presenter: Dmitriy N. Feldman

August 30, 2017

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

Presentation

Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With DES

August 07, 2017

Presentation ACC 2017

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Presenter: Jeff Weitz

March 20, 2017

Presentation

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Presenter: Muthia Vaduganathan

March 22, 2016

Presentation

Stopping vs Continuing Aspirin Before Coronary Artery Surgery

Presenter: Paul Myles

February 24, 2016

Presentation

Efficacy, Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing PCI

Presenter: Matteo Bianco

January 20, 2016

Presentation

Association of Discharge Aspirin Dose With Outcomes After Acute MI

Presenter: Ying Xian

May 27, 2015

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Presentation

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Presenter: Martine Gilard

March 10, 2015

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Advertisement

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

IMPACT: Improving coronary graft Patency with postoperative Aspirin and Clopidogrel versus Aspirin and Ticagrelor

ASCEND Randomized placebo-controlled trial of aspirin

Case: Immediately after PCI and BAV the patient was given aspirin 250 mg iv and Plavix 300 mg

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Aspirin and ADP Antagonists Pre and Post Coronary Stent Implantation

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With DES

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Stopping vs Continuing Aspirin Before Coronary Artery Surgery

Efficacy, Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing PCI

Association of Discharge Aspirin Dose With Outcomes After Acute MI

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content